一句话亮点

这项研究通过全基因组CRISPR筛选，揪出了TRAPPC4这个调控铁死亡抵抗的关键蛋白——它通过关闭TRIM55对GPX4的泛素化降解，让头颈鳞癌（HNSCC）细胞硬抗铁死亡打击，顺带还促进了转移；而老药匹伐他汀（PTV）能靶向降解TRAPPC4，让RSL3重新"奏效"。

背景/痛点

头颈鳞癌（HNSCC）诊断时多为晚期，预后差，特别是HPV阴性亚型对现有治疗响应不佳。铁死亡作为一种铁依赖的脂质过氧化驱动的细胞死亡，近年被认为是潜在的抗癌突破口。但癌细胞也不傻——它们会想方设法增强铁死亡抵抗。GPX4是铁死亡的核心"刹车"，负责清除脂质过氧化物。问题来了：肿瘤细胞到底是怎么稳住GPX4的？有没有可干预的靶点？这篇研究就从这个疑问出发，用无偏筛选去找答案。

推理链分步拆解

第一步：CRISPR筛选锁定TRAPPC4——谁在暗中"维稳"？

研究者先用RSL3（GPX4抑制剂）测试了5株HNSCC细胞，挑出最耐药的LIU-LSC-1，然后做全基因组CRISPR-Cas9敲除筛选。在RSL3处理下，sgRNA被耗竭的基因就是铁死亡抵抗所必需的——结果TRAPPC4排在前列，且是唯一在多组学交叉验证中（转录组、蛋白组、生存数据）全面符合"肿瘤中高表达且与不良预后相关"的候选。敲除TRAPPC4后，RSL3诱导的细胞死亡、脂质ROS和MDA显著增加，线粒体出现典型的铁死亡形态损伤。而过表达则刚好相反。

@方法论点评：CRISPR筛选的最大魅力在于无偏性——不预设假设，让数据说话。这里还用了多组学交叉验证（TCGA+CPTAC+生存分析）来"筛选候选中的候选"，减少了假阳性风险。关键一步是加了Fer-1（铁死亡抑制剂）、Z-VAD（凋亡抑制剂）和Nec-1（坏死性凋亡抑制剂）来做"死亡类型鉴定"，严谨排除了其他死亡方式的干扰。⭐⭐⭐

Fig. 1：Unbiased CRISPR–Cas9 library screening and validation identified TRAPPC4 (TRA) as a critical protein in ferroptosis resistance. A, Flowchart of genome-wide CRISPR screening in LIU-LSC-1 cells to identify ferroptosis-regulating genes. B, Ranking of screened genes by the RRA score, with the top five candidates labeled. C, Line plot showing the depletion of TRA-targeting sgRNAs following RSL3 treatment. D, Western blot analysis of TRA expression in indicated cells.

Fig. 1. Unbiased CRISPR–Cas9 library screening and validation identified TRAPPC4 (TRA) as a critical protein in ferroptosis resistance. A, Flowchart of genome-wide CRISPR screening in LIU-LSC-1 cells to identify ferroptosis-regulating genes. B, Ranking of screened genes by the RRA score, with the top five candidates labeled. C, Line plot showing the depletion of TRA-targeting sgRNAs following RSL3 treatment. D, Western blot analysis of TRA expression in indicated cells.（图注取自PDF文本层，来源：Cancer Research, 2026）

第二步：体内模型验证——敲除TRAPPC4确实能让铁死亡"打进去"

CDX模型中，TRAPPC4敲除联合RSL3显著抑制肿瘤生长，MDA和4-HNE（脂质过氧化标志物）上升，Ki-67下降。PDO模型（患者来源类器官）也得到了一致结果。更关键的是4NQO诱导的致癌物原位小鼠模型——上皮特异性敲除Trappc4后，舌部肿瘤病灶面积减少，而加上RSL3效果更强，且4-HNE信号明显增强。

@方法论点评：从CDX到PDO再到转基因原位模型，体外→体内→患者相关模型逐级递进。特别是4NQO模型模拟了化学致癌过程，比单纯移植瘤更接近真实HNSCC发生发展。这步的核心逻辑是：如果TRAPPC4只是体外现象，那在体内多重模型中复现才有临床转化价值。

Fig. 2：TRAPPC4 deficiency enhances ferroptosis sensitivity in HNSCC CDX and PDO models. A, Schematic of the subcutaneous xenograft model and RSL3 treatment schedule in nude mice. LIU-LSC-1 cells (sgNTC or sgTRA-1) were xenografted into mice and treated with RSL3 (40 mg/kg, i.p.) every other day from days 14 to 30. B–D, Tumor images at the endpoint (B), tumor growth curves (C), and tumor weight (D, left) and relative MDA levels (D, right) in the indicated groups. Scale bars, 1 cm. E and F, Representative IHC images of TRA, Ki-67, and 4-HNE proteins in the indicated xenograft tumors (E), along with quantification of Ki-67 (F, left)

Fig. 2. TRAPPC4 deficiency enhances ferroptosis sensitivity in HNSCC CDX and PDO models. A, Schematic of the subcutaneous xenograft model and RSL3 treatment schedule in nude mice. LIU-LSC-1 cells (sgNTC or sgTRA-1) were xenografted into mice and treated with RSL3 (40 mg/kg, i.p.) every other day from days 14 to 30. B–D, Tumor images at the endpoint (B), tumor growth curves (C), and tumor weight (D, left) and relative MDA levels (D, right) in the indicated groups. Scale bars, 1 cm. E and F, Representative IHC images of TRA, Ki-67, and 4-HNE proteins in the indicated xenograft tumors (E), along with quantification of Ki-67 (F, left)（图注取自PDF文本层，来源：Cancer Research, 2026）

Fig. 3：Trappc4 deficiency promotes the sensitivity of 4NQO-induced autochthonous HNSCC to RSL3 in mice. A, Diagram of the induction process of TraCtrl and TracKO

Fig. 3. Trappc4 deficiency promotes the sensitivity of 4NQO-induced autochthonous HNSCC to RSL3 in mice. A, Diagram of the induction process of TraCtrl and TracKO（图注取自PDF文本层，来源：Cancer Research, 2026）

第三步：机制深挖——TRAPPC4是怎么稳住GPX4的？

敲除TRAPPC4后，GPX4蛋白水平下降但mRNA不变，提示是翻译后调控。CHX（蛋白合成抑制剂）追降解实验显示GPX4在TRAPPC4缺失时降解加速，且MG132（蛋白酶体抑制剂）能阻断这种降解，而溶酶体抑制剂则不能。

4D-DIA蛋白质组学显示，铁死亡通路是变化最显著的通路，而GPX4是唯一在TRAPPC4敲除后显著下调的铁死亡核心蛋白。回补GPX4能逆转TRAPPC4敲除导致的铁死亡敏感。通过IP-MS、RNA-seq和ATAC-seq交叉分析，TRIM55浮出水面——它直接结合GPX4并介导其K48连接的泛素-蛋白酶体降解。TRAPPC4敲除会上调TRIM55，TRIM55敲低则能逆转TRAPPC4敲除对GPX4的下调效应。

@方法论点评：这里有个漂亮的逻辑链条——既然GPX4蛋白水平变化而mRNA不变，那就是蛋白稳定性问题。然后CHX追降解+MG132阻断实验一步步锁定"泛素-蛋白酶体"通路，而非自噬/溶酶体。IP-MS、RNA-seq、ATAC-seq三组学交叉取交集找到TRIM55，是典型的多组学"漏斗式"筛选策略，有效降低了候选基因数量，提高了可信度。K48 vs K63泛素链的区分实验也做得干净，直接点明了降解信号的化学本质。

Fig. 4：TRAPPC4 promotes ferroptosis resistance by upregulating GPX4. A, Volcano plot of 4D-DIA proteomics showing differentially expressed proteins between sgTRA-1 and sgNTC cells (|log2FC| > 0.585, P < 0.05). B, KEGG enrichment analysis of the top 10 enriched pathways from differentially expressed proteins.

Fig. 4. TRAPPC4 promotes ferroptosis resistance by upregulating GPX4. A, Volcano plot of 4D-DIA proteomics showing differentially expressed proteins between sgTRA-1 and sgNTC cells (|log2FC| > 0.585, P < 0.05). B, KEGG enrichment analysis of the top 10 enriched pathways from differentially expressed proteins.（图注取自PDF文本层，来源：Cancer Research, 2026）

Fig. 5：TRAPPC4 inhibits TRIM55-driven ubiquitination and degradation of GPX4 to promote ferroptosis resistance. A, Workflow of IP-MS to identify GPX4-interacting proteins in LIU-LSC-1 cells. B, Venn diagram showing the overlap of identified genes and proteins from RNA-seq, 4D-DIA, ATAC-seq, and IP-MS datasets. C–E, Western blot and qRT-PCR analyses of TRIM55 protein and mRNA levels in LIU-LSC-1 cells with TRAPPC4 knockout (C and D) and TU177 cells with TRA overexpression (E). F, Endogenous interaction between TRIM55 and GPX4 detected by co-IP in LIU-LSC-1 cells. G, Western blot analysis of input and GST pull- down precipitates from MYC–GPX4 incubated with GST or GST-TRIM55 protein. H and I, Western blot and qRT-PCR analyses of GPX4 expression after TRIM55 knockdown in LIU-LSC-1 cells (H) and TRIM55 overexpression in TU177 cells (I). J and K, Western blot (J) and quantification of GPX4 protein levels (K) in TU177 cells transduced with Lv or LvTRIM55 and treated with CHX for the indicated times. L, Western blot analysis of GPX4 in TU177 cells with or without TRIM55 overexpression, treated with DMSO or MG132 (20 µmol/L, 8 hours). M and N, Western blot analysis of the input and IP samples derived from lysates of HEK293T cells transfected with the indicated constructs. O, Western blot analysis of TRA, TRIM55, and GPX4 expression in LIU-LSC-1 cells with the indicated treatments. P, Cell viability of indicated cells treated with different concentrations of RSL3 for 12 hours. Q and R, Relative MDA levels (Q) and L-ROS levels (R) in the indicated cells treated with DMSO or RSL3 (4 µmol/L, 12 hours). Data are presented as the mean ± SD; n ¼ 3 (D, E, H, I, K, and Q) or n ¼ 5 (P). ns, not significant; , P < 0.05; , P < 0.001; , P < 0.0001. A, Created in BioRender. Ding, Z. (2026) https://BioRender.com/ih7t281.

Fig. 5. TRAPPC4 inhibits TRIM55-driven ubiquitination and degradation of GPX4 to promote ferroptosis resistance. A, Workflow of IP-MS to identify GPX4-interacting proteins in LIU-LSC-1 cells. B, Venn diagram showing the overlap of identified genes and proteins from RNA-seq, 4D-DIA, ATAC-seq, and IP-MS datasets. C–E, Western blot and qRT-PCR analyses of TRIM55 protein and mRNA levels in LIU-LSC-1 cells with TRAPPC4 knockout (C and D) and TU177 cells with TRA overexpression (E). F, Endogenous interaction between TRIM55 and GPX4 detected by co-IP in LIU-LSC-1 cells. G, Western blot analysis of input and GST pull- down precipitates from MYC–GPX4 incubated with GST or GST-TRIM55 protein. H and I, Western blot and qRT-PCR analyses of GPX4 expression after TRIM55 knockdown in LIU-LSC-1 cells (H) and TRIM55 overexpression in TU177 cells (I). J and K, Western blot (J) and quantification of GPX4 protein levels (K) in TU177 cells transduced with Lv or LvTRIM55 and treated with CHX for the indicated times. L, Western blot analysis of GPX4 in TU177 cells with or without TRIM55 overexpression, treated with DMSO or MG132 (20 µmol/L, 8 hours). M and N, Western blot analysis of the input and IP samples derived from lysates of HEK293T cells transfected with the indicated constructs. O, Western blot analysis of TRA, TRIM55, and GPX4 expression in LIU-LSC-1 cells with the indicated treatments. P, Cell viability of indicated cells treated with different concentrations of RSL3 for 12 hours. Q and R, Relative MDA levels (Q) and L-ROS levels (R) in the indicated cells treated with DMSO or RSL3 (4 µmol/L, 12 hours). Data are presented as the mean ± SD; n ¼ 3 (D, E, H, I, K, and Q) or n ¼ 5 (P). ns, not significant; , P < 0.05; , P < 0.001; , P < 0.0001. A, Created in BioRender. Ding, Z. (2026) https://BioRender.com/ih7t281.（图注取自PDF文本层，来源：Cancer Research, 2026）

第四步：上游信号——TRAPPC4敲除后，谁打开了TRIM55的开关？

ATAC-seq发现TRAPPC4敲除后，TRIM55上游约2.8kb处的一个远端调控元件染色质开放性增加。转录因子footprinting和motif分析指向FOS。CUT&Tag证实FOS结合该区域。双荧光素酶报告基因实验表明FOS通过该区域的两个结合基序激活转录，且两个基序都突变后激活几乎消失。FOS敲低能部分逆转TRAPPC4敲除导致的TRIM55上调与GPX4下调。

@方法论点评：从表观遗传层面找上游调控因子的思路非常清晰：ATAC-seq看染色质"开门"→motif分析找可能的转录因子→CUT&Tag验证转录因子结合→报告基因验证调控元件功能→功能验证确认因果关系。层层推进，不跳步。而且这里用一个"沉默围观者"的对照组说明：TRAPPC4对FOS的调控是位点特异性的，而不是全局开启FOS活性。⭐⭐⭐⭐

Fig. 6：TRAPPC4 knockout enhances FOS binding to the TRIM55 upstream distal regulatory element and promotes its transcription. A, Average normalized ATAC-seq signal intensity (top) and corresponding heatmaps (bottom) for regions with significantly altered chromatin accessibility (gain or loss) within ±3 kb of peak centers in sgNTC and sgTRA-1 cells. B, IGV tracks display normalized ATAC-seq and RNA-seq signals in sgNTC and sgTRA-1 cells, illustrating chromatin accessibility and TRIM55 mRNA expression levels across three biological replicates. C, Genome-wide FOS transcription factor footprint. D and E, Western blot (D) and qRT-PCR (E) analyses of FOS, TRIM55, and GPX4 levels in sgTRA-1 cells transfected with siFOS-1, siFOS-2, or siNC. F and G, Western blot (F) analysis of FOS, TRIM55, and GPX4 expression and qRT-PCR (G) measurement of their relative mRNA levels in TU177 cells transduced with Lv or LvFOS. H, Heatmap of the genome-wide distribution of FOS antibody binding signals in sgTRA-1 cells generated by CUT&Tag. I, Genome browser snapshot showing overlapping chromatin accessibility from ATAC-seq (region: 66123874–66124273) and FOS-binding signals from CUT&Tag (region: 66122788–66125972) at the upstream distal regu- latory element of TRIM55. J, Schematic representation of putative FOS-binding sites within a distal regulatory element upstream of the TRIM55 gene. K, HEK293T cells were cotransfected with pTRIM55wt-Luc or mutant constructs (pTRIM55 M1-, M2-, or M1+2-Luc), together with pcDNA3.1-FOS or empty vector (pcDNA3.1) and the internal control plasmid pRL-TK. Relative luciferase activity was measured 24 hours after transfection using the dual-luciferase assay. L, The enrichment of FOS in the distal regulatory element upstream of TRIM55 was analyzed by ChIP-PCR assay. M and N, ChIP-qPCR analysis of FOS enrichment at the upstream distal regulatory element of TRIM55 in LvFOS and Lv cells (M) and sgTRA-1 and sgNTC cells (N). Data are presented as the mean ± SD; n ¼ 3 (E, G, K, M, and N). ns, not significant; , P < 0.0001.

Fig. 6. TRAPPC4 knockout enhances FOS binding to the TRIM55 upstream distal regulatory element and promotes its transcription. A, Average normalized ATAC-seq signal intensity (top) and corresponding heatmaps (bottom) for regions with significantly altered chromatin accessibility (gain or loss) within ±3 kb of peak centers in sgNTC and sgTRA-1 cells. B, IGV tracks display normalized ATAC-seq and RNA-seq signals in sgNTC and sgTRA-1 cells, illustrating chromatin accessibility and TRIM55 mRNA expression levels across three biological replicates. C, Genome-wide FOS transcription factor footprint. D and E, Western blot (D) and qRT-PCR (E) analyses of FOS, TRIM55, and GPX4 levels in sgTRA-1 cells transfected with siFOS-1, siFOS-2, or siNC. F and G, Western blot (F) analysis of FOS, TRIM55, and GPX4 expression and qRT-PCR (G) measurement of their relative mRNA levels in TU177 cells transduced with Lv or LvFOS. H, Heatmap of the genome-wide distribution of FOS antibody binding signals in sgTRA-1 cells generated by CUT&Tag. I, Genome browser snapshot showing overlapping chromatin accessibility from ATAC-seq (region: 66123874–66124273) and FOS-binding signals from CUT&Tag (region: 66122788–66125972) at the upstream distal regu- latory element of TRIM55. J, Schematic representation of putative FOS-binding sites within a distal regulatory element upstream of the TRIM55 gene. K, HEK293T cells were cotransfected with pTRIM55wt-Luc or mutant constructs (pTRIM55 M1-, M2-, or M1+2-Luc), together with pcDNA3.1-FOS or empty vector (pcDNA3.1) and the internal control plasmid pRL-TK. Relative luciferase activity was measured 24 hours after transfection using the dual-luciferase assay. L, The enrichment of FOS in the distal regulatory element upstream of TRIM55 was analyzed by ChIP-PCR assay. M and N, ChIP-qPCR analysis of FOS enrichment at the upstream distal regulatory element of TRIM55 in LvFOS and Lv cells (M) and sgTRA-1 and sgNTC cells (N). Data are presented as the mean ± SD; n ¼ 3 (E, G, K, M, and N). ns, not significant; , P < 0.0001.（图注取自PDF文本层，来源：Cancer Research, 2026）

第五步：转移表型与药物干预——TRAPPC4不仅抗铁死亡，还帮癌细胞"跑路"

TRAPPC4敲除后细胞的迁移和侵袭能力下降，Fer-1能逆转。脚垫-腘窝淋巴结转移模型和尾静脉肺转移模型中，TRAPPC4敲除显著减少转移灶，Lip-1（铁死亡抑制剂）则能逆转。虚拟筛选从5035个化合物中找到了匹伐他汀（PTV）能结合TRAPPC4并促其降解。CETSA、DARTS、SPR验证了直接结合。PTV联合RSL3在PDO、PDX和4NQO原位模型中均显示出协同抑制肿瘤生长和转移的效果，且在TRAPPC4敲除细胞中PTV效果减弱，说明其依赖TRAPPC4。

@方法论点评：转移模型的设计值得一学——脚垫模型模拟淋巴转移，尾静脉模型模拟血行肺转移，覆盖了HNSCC两种主要转移途径。而且用Fer-1/Lip-1来"回补"转移能力，证明了转移抑制是铁死亡介导的，而非脱靶效应。药物筛选部分从虚拟筛选到体外验证再到体内模型，逻辑链条完整。CETSA和DARTS是验证"药物-靶点直接结合"的经典热力学和酶解方法，加上SPR测亲和力，三重验证保证了PTV确实结合TRAPPC4，而不是间接效应。⭐⭐⭐⭐

Fig. 7：TRAPPC4 promotes HNSCC metastasis by inhibiting ferroptosis. A, Representative images showing migration and invasion in indicated cells treated with DMSO or Fer-1 (1 µmol/L, 24 hours). B, Quantification of cell migration (B, left) and invasion (B, right) in each condition. C, Schematic of the footpad-popliteal lymph node metastasis model in LIU-LSC-1 cells (sgNTC or sgTRA-1, 5 \x03 106). Lip-1 (5 mg/kg, i.p.) was administered every other day from day 15 to day 45, for a total of 15 doses. D and E, Popliteal lymph node images (D) and volume (E) in different groups. F, Representative images display the CK5/6 immunostaining of popliteal lymph nodes and the quantification of metastatic areas across different groups. G, Representative IHC images (G, left) and quantitative analysis (G, right) of LYVE1-marked lymphatic vessel density in the footpad tumor tissues of the indicated groups. H, Schematic flowchart of the lung metastasis model. LIU-LSC-1 cells (sgNTC or sgTRA-1, 1 \x03 106) were injected, and Lip-1 (5 mg/kg, i.p.) was administered every other day from day 15 to day 45, for a total of 15 doses. I, The number of metastatic lung nodules was quantified. J, Representative images of the lung and H&E-stained lung sections are presented. K, The lung metastatic nodules (K, left) and weights (K, right) of all animals were summarized. Data are presented as the mean ± SD; n ¼ 3 (B). , P < 0.05; , P < 0.01; , P < 0.0001. i.p., intraperitoneally.

Fig. 7. TRAPPC4 promotes HNSCC metastasis by inhibiting ferroptosis. A, Representative images showing migration and invasion in indicated cells treated with DMSO or Fer-1 (1 µmol/L, 24 hours). B, Quantification of cell migration (B, left) and invasion (B, right) in each condition. C, Schematic of the footpad-popliteal lymph node metastasis model in LIU-LSC-1 cells (sgNTC or sgTRA-1, 5  106). Lip-1 (5 mg/kg, i.p.) was administered every other day from day 15 to day 45, for a total of 15 doses. D and E, Popliteal lymph node images (D) and volume (E) in different groups. F, Representative images display the CK5/6 immunostaining of popliteal lymph nodes and the quantification of metastatic areas across different groups. G, Representative IHC images (G, left) and quantitative analysis (G, right) of LYVE1-marked lymphatic vessel density in the footpad tumor tissues of the indicated groups. H, Schematic flowchart of the lung metastasis model. LIU-LSC-1 cells (sgNTC or sgTRA-1, 1  106) were injected, and Lip-1 (5 mg/kg, i.p.) was administered every other day from day 15 to day 45, for a total of 15 doses. I, The number of metastatic lung nodules was quantified. J, Representative images of the lung and H&E-stained lung sections are presented. K, The lung metastatic nodules (K, left) and weights (K, right) of all animals were summarized. Data are presented as the mean ± SD; n ¼ 3 (B). , P < 0.05; , P < 0.01; , P < 0.0001. i.p., intraperitoneally.（图注取自PDF文本层，来源：Cancer Research, 2026）

Fig. 8：PTV targets TRAPPC4 to enhance the effects of RSL3 treatment in HNSCC. A, Virtual screening of TRA (PDB: 2J3T) docked against the HY-L035P Drug Repurposing Compound Library Plus, comprising 5,035 compounds. B, The binding between PTV and TRAPPC4 in 2D. C and D, Western blot analysis of TRA expression following cellular thermal shift assay to assess its thermodynamic binding with PTV (10 µmol/L, 2 hours). E, Western blot analysis of TRA expression in LIU-LSC-1 cell lysates treated with varying concentrations of PTV and incubated with Pronase E. F, SPR binding affinity measurements between PTV and TRA. G, Western blot analysis of TRA and GPX4 expression in LIU-LSC-1 cells treated by PTV (10 µmol/L) for 12 hours. H and I, Representative images of PDOs treated with RSL3 (10 µmol/L, 48 hours), PTV (20 µmol/L, 48 hours), and the combination of PTV and RSL3 (H); statistical analysis of PDO viability (I). J–L, Images of

Fig. 8. PTV targets TRAPPC4 to enhance the effects of RSL3 treatment in HNSCC. A, Virtual screening of TRA (PDB: 2J3T) docked against the HY-L035P Drug Repurposing Compound Library Plus, comprising 5,035 compounds. B, The binding between PTV and TRAPPC4 in 2D. C and D, Western blot analysis of TRA expression following cellular thermal shift assay to assess its thermodynamic binding with PTV (10 µmol/L, 2 hours). E, Western blot analysis of TRA expression in LIU-LSC-1 cell lysates treated with varying concentrations of PTV and incubated with Pronase E. F, SPR binding affinity measurements between PTV and TRA. G, Western blot analysis of TRA and GPX4 expression in LIU-LSC-1 cells treated by PTV (10 µmol/L) for 12 hours. H and I, Representative images of PDOs treated with RSL3 (10 µmol/L, 48 hours), PTV (20 µmol/L, 48 hours), and the combination of PTV and RSL3 (H); statistical analysis of PDO viability (I). J–L, Images of（图注取自PDF文本层，来源：Cancer Research, 2026）

核心结论

这条信号轴画出来是这样的：TRAPPC4 → （抑制）BEND3 → （维持异染色质状态）→ 限制FOS结合TRIM55远端增强子 → TRIM55转录低 → GPX4泛素化降解减少 → GPX4蛋白稳定 → 铁死亡抵抗。TRAPPC4敲除后，BEND3减少，染色质开放，FOS结合增强，TRIM55转录上调，GPX4被TRIM55介导的K48泛素化降解，铁死亡敏感性增加。PTV结合TRAPPC4促其降解，相当于模拟了TRAPPC4敲除的效果，与RSL3协同增效。

对耐药/DTP/PGCC 的启示

铁死亡抵抗可能是DTP细胞存活的新维度：文中TRAPPC4敲除后迁移侵袭能力下降，而Fer-1挽救，提示DTP细胞可能通过上调TRAPPC4-GPX4轴抵抗铁死亡来维持"静默存活"状态。或许在靶向治疗压力下，残存的DTP细胞正是靠这一机制躲过一劫——检测TRAPPC4/GPX4在DTP中的表达变化值得一试。 PTV老药新用，靶向铁死亡抵抗有临床转化捷径：匹伐他汀已上市，安全性数据丰富，如果能在HNSCC临床样本中验证TRAPPC4高表达作为疗效预测标志物，联合RSL3类似物开展临床研究可能比从头开发新药快得多。对于PGCC（常表现为多倍体、基因组不稳定）这种"难搞"细胞，铁死亡诱导策略是否同样有效值得探索。 TRIM55作为一个丢失的"刹车"：HNSCC中TRIM55表达显著低于正常组织，这相当于癌细胞主动"拆掉"了降解GPX4的机制。从肿瘤进化的角度看，这可能是HNSCC选择性地沉默一个抑癌样E3连接酶来适应氧化应激。靶向恢复TRIM55表达或活性，也是一种潜在策略——至于是否有小分子能激活TRIM55，文中未探讨。

局限

TRAPPC4调控BEND3的机制细节未完全阐明——是直接结合还是间接影响？BEND3是否直接结合TRIM55远端增强子？文中承认这一点需要后续靶向染色质分析。 FOS作为TRIM55转录激活因子，但TRAPPC4如何"限制"FOS结合——是通过BEND3改变染色质状态还是其他方式？BEND3与FOS之间有无直接相互作用？ PTV降解TRAPPC4的具体分子机制未完全解析：是促进TRAPPC4自身泛素化？什么E3连接酶介导？文中只展示了PTV促进TRAPPC4泛素化，但具体酶未鉴定。 铁死亡与转移之间的因果关系在体内没有用"铁死亡标志物+转移终点"做中介分析，Lip-1挽救实验是反向验证，证据强度足够但缺一层直接机制联系。

来源

期刊：Cancer Research，2026。DOI: 10.1158/0008-5472.CAN-25-3654